fashion -WSS

fashion

author：knowledge 2025-09-30 00:47:12 - browse：4

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

focus

WSS

Congress must reauthorize a committee to support older Americans

Making the case for fair compensation in clinical trials

Reports of telehealth's death have been greatly exaggerated

PBM reforms clear House panel

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Wegovy, Zepbound and weight loss drugs that preserve muscle

hotspot

fashion

hotspot

Heart attack and stroke risk calculators need revising

Liver decline slowed by off

Trump demands the U.S. pay no more for drugs than other countries … again

Why medical students are struggling with mental health

Walensky prepares to leave CDC — and Congress — behind

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Duchenne breakthrough therapy leaves behind pioneering families

Making the case for fair compensation in clinical trials

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA poised to publish guidelines for clinical trial diversity

leisure time

In key trial, Verve's treatment lowers cholesterol levels in patients

A daunting task: navigating dual Medicare, Medicaid eligibility

FDA's Woodcock to retire early next year

Liver decline slowed by off

Addressing health care workers' trauma can help fight burnout

PBM reforms clear House panel

explore

focus

knowledge

leisure time